Bluejay Diagnostics (NASDAQ:BJDX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Bluejay Diagnostics (NASDAQ:BJDX) from a hold rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Stock Down 3.3%

Shares of NASDAQ:BJDX opened at $0.87 on Friday. The firm has a fifty day moving average of $1.28 and a two-hundred day moving average of $2.01. Bluejay Diagnostics has a 12-month low of $0.83 and a 12-month high of $16.68. The firm has a market capitalization of $3.89 million, a P/E ratio of -0.12 and a beta of 0.89.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Insider Transactions at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider directly owned 92,055 shares in the company, valued at $128,877. The trade was a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.